Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Net Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Net Margin for 6 consecutive years, with 14.61% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 2028.0% to 14.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.92%, a 1221.0% increase, with the full-year FY2025 number at 4.92%, up 1221.0% from a year prior.
  • Net Margin was 14.61% for Q4 2025 at GeneDx Holdings, down from 6.54% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 6393.49% in Q2 2021 to a low of 503.2% in Q4 2022.
  • A 5-year average of 211.04% and a median of 57.19% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: crashed -663055bps in 2022, then skyrocketed 45834bps in 2023.
  • GeneDx Holdings' Net Margin stood at 69.52% in 2021, then plummeted by -624bps to 503.2% in 2022, then skyrocketed by 91bps to 44.86% in 2023, then soared by 113bps to 5.66% in 2024, then tumbled by -358bps to 14.61% in 2025.
  • Per Business Quant, the three most recent readings for WGS's Net Margin are 14.61% (Q4 2025), 6.54% (Q3 2025), and 10.53% (Q2 2025).